Literature DB >> 15085153

Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.

V R Lo Vasco1, G Calabrese, L Manzoli, G Palka, A Spadano, E Morizio, P Guanciali-Franchi, D Fantasia, L Cocco.   

Abstract

Myelodysplastic syndrome (MDS) is an adult hematological disease that evolves into acute myeloid leukemia (AML) in about 30% of the cases. The availability of a highly specific probe moved us to perform in patients affected with MDS/AML, associated with normal karyotype, painting and fluorescence in situ hybridization (FISH) analysis aimed to check the inositide-specific phospholipase C (PI-PLC) beta1 gene, a player in the control of some checkpoints of the cell cycle. Here we present a preliminary observation in which FISH analysis disclosed in a small group of MDS/AML patients with normal karyotype the monoallelic deletion of the PI-PLCbeta1 gene. On the contrary, PI-PLC beta4, another gene coding for a signaling molecule, located on 20p12.3 at a distance as far as less than 1Mb from PI-PLCbeta1, is unaffected in MDS patients with the deletion of PI-PLC beta1 gene, hinting at an interstitial deletion. The MDS patients, bearing the deletion, rapidly evolved to AML. The data suggest the possible involvement of PI-PLCbeta1 in the progression of the disease and pave the way for a larger investigation aimed at identifying a possible high-risk group among MDS patients with a normal karyotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085153     DOI: 10.1038/sj.leu.2403368

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

Review 1.  Immune regulation by phospholipase C-β isoforms.

Authors:  Wenbin Xiao; Yuko Kawakami; Toshiaki Kawakami
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

2.  Signalling in the genomic era.

Authors:  Vincenza Rita Lo Vasco
Journal:  J Cell Commun Signal       Date:  2010-06-06       Impact factor: 5.782

3.  Small molecule inhibitors of phospholipase C from a novel high-throughput screen.

Authors:  Weigang Huang; Matthew Barrett; Nicole Hajicek; Stephanie Hicks; T Kendall Harden; John Sondek; Qisheng Zhang
Journal:  J Biol Chem       Date:  2013-01-07       Impact factor: 5.157

4.  Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.

Authors:  W J Chng; M A Gertz; T-H Chung; S Van Wier; J J Keats; A Baker; P L Bergsagel; J Carpten; R Fonseca
Journal:  Leukemia       Date:  2010-03-11       Impact factor: 11.528

5.  Ezrin-related Phosphoinositide pathway modifies RhoA and Rac1 in human osteosarcoma cell lines.

Authors:  V R Lo Vasco; M Leopizzi; C Della Rocca
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

Review 6.  The basis of nuclear phospholipase C in cell proliferation.

Authors:  Dawidson Assis Gomes; Marcelo Coutinho de Miranda; Jerusa Araújo Quintão Arantes Faria; Michele Angela Rodrigues
Journal:  Adv Biol Regul       Date:  2021-10-23

Review 7.  A novel gene expression pathway regulated by nuclear phosphoinositides.

Authors:  David L Mellman; Richard A Anderson
Journal:  Adv Enzyme Regul       Date:  2009

8.  Ezrin silencing remodulates the expression of Phosphoinositide-specific Phospholipase C enzymes in human osteosarcoma cell lines.

Authors:  V R Lo Vasco; M Leopizzi; C Puggioni; C Della Rocca
Journal:  J Cell Commun Signal       Date:  2014-07-30       Impact factor: 5.782

9.  U-73122 reduces the cell growth in cultured MG-63 ostesarcoma cell line involving Phosphoinositide-specific Phospholipases C.

Authors:  Vincenza Rita Lo Vasco; Martina Leopizzi; Valeria Di Maio; Carlo Della Rocca
Journal:  Springerplus       Date:  2016-02-24

10.  PLCB4 upregulation is associated with unfavorable prognosis in pediatric acute myeloid leukemia.

Authors:  Shiwen Wu; Wei Zhang; Dongqin Shen; Jianle Lu; Li Zhao
Journal:  Oncol Lett       Date:  2019-09-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.